Overall Survival and Prognostic Factors for Breast Cancer Patients at Vachira Phuket Hospital

Authors

  • Smith Soimadee Division of Surgery, Vachira Phuket Hospital

Keywords:

breast cancer, survival rate, stage at diagnosis, prognostic factors

Abstract

This retrospective study analyzed the 5-year survival rate and prognostic factors among breastcancer patients at Vachira Phuket Hospital, Thailand. The study included 253 new female breast cancer patients diagnosed during the period 1 January 2007 to 31 December 2011 and followed up until the end of 2015. The clinico-pathological data of the patients were collected for evaluation. It was found that 83 cases (32.80%) had died and 170 cases (67.2%) were still alive. The overall survival rate at 5 years was 65.5%. The 5-year survival rates for stages I, II, III, and IV were 82.4%, 79.2%, 45.3% and 0%, respectively. When analysis was conducted by stages combined into 2 groups--early (stages I and II) and late (stages III and IV)--the 5-year survival rate for early stage (80.3%) was higher than for late stage (43.2%) (P<0.001). Patients with late stage (III and IV) showed higher rate of death than early stage (I and II)( (hazard ratio=3.922; P<0.001). Patients with luminal B and triple negative subtypes had shorter survival times than luminal A subtype (P<0.05). In addition, the findings showed that the stages at diagnosis and metastasis affected patient survival rate. The adjusted hazard ratio of patients with stage III and IV were 4.1 (P=0.003) and 11.86 (P<0.001), respectively, compared with stage I. Patients with metastasis had an adjusted hazard ratio of 2.72 (P<0.001), compared with the non-metastatic group. These findings indicate that early diagnosis increased overall survival rates among breast-cancer patients.

References

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v 1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer; 2013.

Imsamran W, Chaiwerawattana A, Wiangnon S, Pongnikorn D, Suwanrungrung K, Sangrajrang S, et al. Cancer in Thailand: Vol. VIII, 2010-2012. Bangkok: New Thammada Press (Thailand) Co., Ltd; 2015.

Chaiwerawattana A, Loawahutanon P, Suwankason P. Hospital-based cancer registry annual report 2012. Bangkok: Eastern Printing Public Company Limited PCL. 157; 2014.

Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2013. Available at: http://seer.cancer.gov/csr/1975_2013/. Accessed December 30, 2015.

วรางคณา จันทรสุข, ดุสิต สุจิรารัตน์, อรุณรักษ์ คูเปอร์มีใย, อาคม ชัยวีระวัฒนะ. การศึกษาปัจจัยในการพยากรณ์และการรอดชีพของผู้ป่วยมะเร็งเต้านม ณ สถาบันมะเร็งแห่งชาติ. ใน: รัตติยากร วิมลศิริ, พาณิภัค พระชัย, ดิลกรัตน์ โคตรสุมาตย์, อภิเชษฐ์ บุญจวง, ปัทมาสมพงษ์, พรนภา โยธาฤทธิ์และคณะ, บรรณาธิการ. เอกสารรวมบทคัดย่อการประชุมวิชาการเสนอผลงานวิจัยระดับบัณฑิตศึกษาครั้ง ที่ 15; 28 มีนาคม 2557; ณ มหาวิทยาลัยขอนแก่น. ขอนแก่น: บัณฑิตวิทยาลัย มหาวิทยาลัยขอนแก่น; 2557. หน้า 1807-13.

Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 2008;9:730-56.

Kotepui M, Chupeerach C. Age distribution of breast cancer from a Thailand population-based cancer registry. Asian Pac J Cancer Prev 2013;14:3815-7.

Somintara O, Somintara S, Suwanrungruang K. Breast cancer in Srinagarind Hospital (2000-2010). Srinagarind Med J 2015;30:87-91.

National Cancer Institute. SEER Stat Fact Sheet; Breast cancer 2014. Available at: http://seer.cancer. gov/statfacts/HTML/breast.html. Accessed December 30, 2015.

Amornsak P, Supot K, Supannee P. Survival rate of breast cancer: A hospital-based study from northeast of Thailand. Asian Pac J Cancer Prev 2012; 13:791-4.

Aphinives P, Punchai S, Vajirodom D, Bhudhisawasdi V. Five-year survival in Srinagarind Hospital, Thailand. J Med Assoc Thai 2010;93:S25-9.

Parise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J 2009;15:593-602.

Minicozzi P, Bella F, Toss A, Giacomin A, Fusco M, Zarcone M, et al. Relative and disease-free survival in breast cancer in relation to subtype: a populationbased study. J Cancer Res Clin Oncol 2013;139: 1569-77.

Ihemelandu CU, Naab TJ, Mezghebe HM, Makambi KH, Siram SM, Leffall LD, et al. Treatment and survival outcome for molecular breast cancer subtypes in black women. Ann Surg 2008;247:463-9.

Kongsiang A, Tangvoraphonkchai V, Jirapornkul C, Promthet S, Kamsa-Ard S, Suwanrungruang K. Survival time and molecular subtypes of breast cancer after radiotherapy in Thailand. Asian Pac J Cancer Prev 2014;15:10505-8.

Downloads

Published

2017-06-30

Issue

Section

Original Articles